TNFRSF9 and hepatitis A virus infection: Agonist CD137 mAbs are the most straightforward and extensively studied modality for activating CD137; however, agonistic mAbs can be associated with severe toxicity, such as hepatitis and inflammatory cytokine production, arising from non-specific and systemic activation of lymphocytes.